(CercleFinance.com) – Merck KGaA presented on Friday follow-up data confirming the long-term positive phase III results obtained by its immunotherapy Bavencio in the treatment of advanced urothelial carcinoma.
These results, obtained over a 38-month observation period, show that the drug provided a median overall survival of 23.8 months in patients with bladder cancer, compared to 15 months for the current standard treatment. .
After 30 months, 43.7% of patients were alive, compared to 33.5% in the reference group.
In patients expressing PD-L1+ markers, median overall survival even reaches 30.9 months, with more than half (51.3%) of patients alive after 30 months.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
